Carisma Therapeutics, Inc.

How big is Carisma Therapeutics, Inc.?

As of Jun 18, Carisma Therapeutics, Inc. has a market capitalization of 18.80 million, categorizing it as a Micro Cap company. As of Jun 24, net sales for the latest four quarters are 19.96 million, with a net profit of -50.77 million.

As of Jun 18, Carisma Therapeutics, Inc. has a market capitalization of 18.80 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 19.96 million, while the sum of net profit for the same period is -50.77 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -27.91 million, and total assets amount to 30.46 million.

What does Carisma Therapeutics, Inc. do?

Carisma Therapeutics, Inc. is a late-stage clinical company developing antibody-drug conjugate therapies for cancer, with a market cap of $18.80 million and recent net sales of $4 million. As of March 2025, it reported a net profit loss of $9 million.

Overview:<BR>Carisma Therapeutics, Inc. is a late-stage clinical company focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 18.80 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.17 <BR>Return on Equity: 138.47% <BR>Price to Book: -0.51 <BR><BR>Contact Details:<BR>Address: 245 1st St Ste 1800, CAMBRIDGE MA: 02142-1292 <BR>Tel: 1 617 4448550 <BR>Fax: 1 617 8580911 <BR>Website: http://www.elevenbio.com/

Should I buy, sell or hold Carisma Therapeutics, Inc.?

Who are in the management team of Carisma Therapeutics, Inc.?

As of March 2022, the management team of Carisma Therapeutics, Inc. includes Dr. Jay Duker (Independent Chairman), Mr. Thomas Cannell (President and CEO), and several independent directors: Ms. Carrie Bourdow, Ms. Jane Henderson, Mr. Jason Keyes, and Mr. Daniel Lynch.

As of March 2022, the management team of Carisma Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Jay Duker, who serves as the Independent Chairman of the Board.<BR>- Mr. Thomas Cannell, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Carrie Bourdow, who is an Independent Director.<BR>- Ms. Jane Henderson, who is also an Independent Director.<BR>- Mr. Jason Keyes, who holds the position of Independent Director.<BR>- Mr. Daniel Lynch, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and executive leadership, with Dr. Jay Duker and Mr. Thomas Cannell in prominent roles.

Is Carisma Therapeutics, Inc. technically bullish or bearish?

As of September 8, 2025, Carisma Therapeutics, Inc. shows a neutral technical trend with mixed indicators, including a mildly bullish weekly MACD and bearish daily moving averages, while significantly underperforming the S&P 500 with a 1-year return of -71.70% and a 5-year return of -98.88%.

As of 8 September 2025, the technical trend for Carisma Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD remains mildly bullish, while the weekly RSI is bearish. Moving averages on the daily timeframe are bearish, and the KST shows a mildly bearish trend on the weekly and bearish on the monthly. The OBV is bullish on both weekly and monthly timeframes, indicating some buying pressure. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -71.70% versus the S&P 500's 17.14%, and a staggering 5-year return of -98.88% compared to the S&P's 96.61%.